You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(601607.SH):“SPH3127片”慢性腎病適應症臨牀申請獲受理
格隆匯 05-19 16:33

格隆匯5月19日丨上海醫藥(601607.SH)宣佈,近日,公司開發的“SPH3127片”慢性腎病適應症臨牀試驗申請獲得國家藥監局的正式受理。

SPH3127片是一種新型口服腎素抑制劑,SPH3127片高血壓適應症正在中國開展Ⅲ期臨牀試驗;輕度至中度潰瘍性結腸炎適應症正在美國開展II期臨牀試驗。

該項目由上海醫藥和日本田邊三菱製藥株式會社合作研發,雙方共同擁有知識產權。公司已向美國、日本、歐洲、澳大利亞、韓國、菲律賓、中國等數十個國家/地區提交該產品的化合物專利申請,並已取得在中國、美國、日本、澳大利亞等數十個國家/地區的授權。截至該公吿日,全球未有同靶點同適應症的藥品上市。

截至目前,該項目已累計投入研發費用716.02萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account